High-dose Enerzair Breezhaler further cuts asthma exacerbations
New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose
Read More
Tag: Enerzair Breezhaler
Novartis banks EC approval for Enerzair Breezhaler
The product includes the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
Read More
CHMP puts eight new medicines forward for approval
The recommendations bring closer to approval new therapies for asthma, acute myeloid leukaemia, transfusion-dependent anaemia, diabetes, prostate cancer, schizophrenia and multiple sclerosis
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
